|
||
|
IDDI S.A.
Download PDF Members: Over the past decade, clinical trials have grown in numbers, size and complexity, and at the same time they have been subject to increasing scrutiny and tightened regulations worldwide. Clinical trials have become hugely expensive, and the need to control them very tightly has become more acute than ever before. The number of published trial results has increased two-fold from just above 700 in 2000 to almost 1500 in 2003. Somewhat disparagingly, however, the number of new drug approvals has actually decreased over the same period, from 160 in 2000 to a mere 115 in 2002! With the number of new molecular entities ready to enter clinical development over the coming years, it will be crucial to control trials as early as possible in order to screen the best drug candidates reliably and expeditiously. The most efficient way to control clinical trials is to make the best possible use of statistical methodology for their design and analysis, and of technology for their conduct. This is IDDI's mission
This page has been viewed 247 times since April 2007, the link to the organisation's website has been followed 33 times Recent Search Terms used to find this page: iddi*tel | iddi clinical | iddi.com | IDDI avenue louise | t | damien tremolet | IDDI S.A. | . Search for more companies in Brussels This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for IDDI S.A. | |||||||||||||||||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|